A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures

Abstract PARP inhibitors are approved for the treatment of solid tumor types that frequently harbor alterations in the key homologous recombination (HR) genes, BRCA1/2. Other tumor types, such as lung cancer, may also be HR deficient, but the frequency of such cases is less well characterized. Speci...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Miklos Diossy, Zsofia Sztupinszki, Judit Borcsok, Marcin Krzystanek, Viktoria Tisza, Sandor Spisak, Orsolya Rusz, Jozsef Timar, István Csabai, Janos Fillinger, Judit Moldvay, Anders Gorm Pedersen, David Szuts, Zoltan Szallasi
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Accès en ligne:https://doaj.org/article/406462c44b26424ba7040c4796c0ef2d
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!